MX384087B - Piperidinas como inhibidores de menina. - Google Patents
Piperidinas como inhibidores de menina.Info
- Publication number
- MX384087B MX384087B MX2018013433A MX2018013433A MX384087B MX 384087 B MX384087 B MX 384087B MX 2018013433 A MX2018013433 A MX 2018013433A MX 2018013433 A MX2018013433 A MX 2018013433A MX 384087 B MX384087 B MX 384087B
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- formula
- menina
- piperidines
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003053 piperidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102100030550 Menin Human genes 0.000 abstract 1
- 101710169972 Menin Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662330350P | 2016-05-02 | 2016-05-02 | |
| PCT/US2017/030577 WO2017192543A1 (en) | 2016-05-02 | 2017-05-02 | Piperidines as menin inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018013433A MX2018013433A (es) | 2019-07-18 |
| MX384087B true MX384087B (es) | 2025-03-14 |
Family
ID=58699299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013433A MX384087B (es) | 2016-05-02 | 2017-05-02 | Piperidinas como inhibidores de menina. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10899738B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3452461B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6991585B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20190015275A (cg-RX-API-DMAC7.html) |
| CN (1) | CN109415337B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017259436B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018072570A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3022868A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2899936T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL262697B (cg-RX-API-DMAC7.html) |
| MX (1) | MX384087B (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201809714TA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017192543A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016040330A1 (en) | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| US10588907B2 (en) | 2015-06-04 | 2020-03-17 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| SI3429591T1 (sl) | 2016-03-16 | 2023-07-31 | Kura Oncology, Inc. | Substituirani tieno(2,3-d)pirimidinski derivati kot inhibitorji menin-MLL in postopki uporabe |
| PH12018501955B1 (en) | 2016-03-16 | 2024-01-24 | Kura Oncology Inc | Bridged bicyclic inhibitors of menin-mll and methods of use |
| WO2017192543A1 (en) | 2016-05-02 | 2017-11-09 | Regents Of The University Of Michigan | Piperidines as menin inhibitors |
| JP7007302B2 (ja) | 2016-06-10 | 2022-01-24 | ヴァイティー ファーマシューティカルズ，エルエルシー | メニン－ｍｌｌ相互作用の阻害剤 |
| MX392051B (es) | 2016-09-14 | 2025-03-21 | Janssen Pharmaceutica Nv | Inhibidores espirobiciclicos de la interaccion de menina-mll |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| CA3033020A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-mll interaction |
| JP7142010B2 (ja) | 2016-12-15 | 2022-09-26 | ヤンセン ファーマシューティカ エヌ．ベー． | メニン－ｍｌｌ相互作用のアゼパン阻害剤 |
| CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
| AU2018243586A1 (en) | 2017-03-31 | 2019-10-17 | The Regents Of The University Of Michigan | Piperidines as covalent menin inhibitors |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| WO2019060365A1 (en) | 2017-09-20 | 2019-03-28 | Kura Oncology, Inc. | SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| CN112105621B (zh) | 2018-03-30 | 2024-02-20 | 住友制药株式会社 | 光学活性桥型环状仲胺衍生物 |
| CN111936465A (zh) * | 2018-03-30 | 2020-11-13 | 密歇根大学董事会 | 作为共价menin抑制剂的哌啶化合物 |
| EP3856173A4 (en) * | 2018-09-26 | 2022-07-06 | Kura Oncology, Inc. | TREATMENT OF HEMOPATHY MALIGNANCE WITH MENIN INHIBITORS |
| SG11202101733TA (en) | 2018-10-03 | 2021-03-30 | Univ Michigan Regents | Small molecule menin inhibitors |
| US11174263B2 (en) | 2018-12-31 | 2021-11-16 | Biomea Fusion, Inc. | Inhibitors of menin-MLL interaction |
| JP7536767B2 (ja) | 2018-12-31 | 2024-08-20 | バイオメア フュージョン，インコーポレイテッド | メニン－ｍｌｌ相互作用の不可逆的阻害剤 |
| WO2021067215A1 (en) | 2019-09-30 | 2021-04-08 | Agios Pharmaceuticals, Inc. | Piperidine compounds as menin inhibitors |
| UA129208C2 (uk) | 2019-12-19 | 2025-02-05 | Янссен Фармацевтика Нв | Заміщені спіропохідні з прямим ланцюгом |
| TW202204334A (zh) | 2020-04-08 | 2022-02-01 | 美商阿吉歐斯製藥公司 | Menin抑制劑及治療癌症之使用方法 |
| TW202204333A (zh) | 2020-04-08 | 2022-02-01 | 美商阿吉歐斯製藥公司 | Menin抑制劑及治療癌症之使用方法 |
| EP4334320A1 (en) | 2021-05-08 | 2024-03-13 | JANSSEN Pharmaceutica NV | Substituted spiro derivatives |
| KR20240006542A (ko) | 2021-05-08 | 2024-01-15 | 얀센 파마슈티카 엔브이 | 치환된 스피로 유도체 |
| EP4337329A4 (en) * | 2021-05-12 | 2025-01-01 | Syndax Pharmaceuticals, Inc. | COMBINATIONS FOR CANCER TREATMENT |
| CR20230605A (es) | 2021-06-01 | 2024-05-24 | Janssen Pharmaceutica Nv | Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos |
| US20250333421A1 (en) | 2021-06-03 | 2025-10-30 | Janssen Pharmaceutica Nv | Pyridazines or 1,2,4-triazines substituted by spirocyclic amines |
| IL309359A (en) | 2021-06-17 | 2024-02-01 | Janssen Pharmaceutica Nv | (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer |
| TW202320796A (zh) | 2021-08-11 | 2023-06-01 | 美商拜歐米富士恩股份有限公司 | 用於糖尿病的menin-mll相互作用之共價抑制劑 |
| TW202313004A (zh) | 2021-08-20 | 2023-04-01 | 美商拜歐米富士恩股份有限公司 | Ｍｅｎｉｎ－ｍｌｌ相互作用之不可逆抑制劑的結晶形式 |
| WO2023056589A1 (en) | 2021-10-08 | 2023-04-13 | Servier Pharmaceuticals Llc | Menin inhibitors and methods of use for treating cancer |
| EP4525873A1 (en) * | 2022-05-17 | 2025-03-26 | Biomea Fusion, Inc. | Flt3 combination therapy for cancer and compositions therefor |
| KR20250109775A (ko) | 2022-11-24 | 2025-07-17 | 오리존 지노믹스 에스.에이. | 암 치료를 위한 lsd1 억제제 및 메닌 억제제의 조합 |
| TW202430528A (zh) | 2023-01-18 | 2024-08-01 | 美商拜歐米富士恩股份有限公司 | Ｎ－［４－［４－（４－嗎啉基）－７ｈ－吡咯並［２，３－ｄ］嘧啶－６－基］苯基］－４－［［３（ｒ）－［（１－氧代－２－丙烯－１－基）氨基］－１－哌啶基］甲基］－２－吡啶甲醯胺的結晶形式作為ｍｅｎｉｎ－ｍｌｌ相互作用的共價抑制劑 |
| CN120987784A (zh) * | 2025-10-23 | 2025-11-21 | 辽宁鸿港化工有限公司 | 一种对甲氧基苄胺及其制备方法和用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| WO1998054167A1 (en) | 1997-05-28 | 1998-12-03 | Mitsubishi-Tokyo Pharmaceuticals, Inc. | Indole compounds |
| US7576082B2 (en) | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
| WO2008070303A2 (en) | 2006-10-19 | 2008-06-12 | The University Of Chicago | Therapeutics to inhibit mll-menin interaction for treating leukemia |
| EP2473054B1 (en) | 2009-09-04 | 2017-06-14 | The Regents of the University of Michigan | Compositions and methods for treatment of leukemia |
| US8946197B2 (en) | 2009-11-16 | 2015-02-03 | Chdi Foundation, Inc. | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof |
| RU2617643C2 (ru) | 2011-05-09 | 2017-04-25 | ФОРМА ТиЭм, ЭлЭлСИ | Новые соединения и композиции для ингибирования nampt |
| BR112015022602A2 (pt) | 2013-03-13 | 2017-07-18 | Univ Michigan Regents | composições compreendendo compostos de tienopirimidina e tienopiridina e métodos de uso dos mesmos |
| US9212180B2 (en) * | 2013-06-12 | 2015-12-15 | The Regents Of The University Of Michigan | Menin-MLL inhibitors and methods of use thereof |
| WO2014200479A1 (en) | 2013-06-12 | 2014-12-18 | The Regents Of The University Of Michigan | Menin-mll inhibitors and methods of use thereof |
| WO2016040330A1 (en) | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| US10588907B2 (en) | 2015-06-04 | 2020-03-17 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| EP3394064A1 (en) | 2015-12-22 | 2018-10-31 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| SI3429591T1 (sl) | 2016-03-16 | 2023-07-31 | Kura Oncology, Inc. | Substituirani tieno(2,3-d)pirimidinski derivati kot inhibitorji menin-MLL in postopki uporabe |
| PH12018501955B1 (en) | 2016-03-16 | 2024-01-24 | Kura Oncology Inc | Bridged bicyclic inhibitors of menin-mll and methods of use |
| WO2017192543A1 (en) | 2016-05-02 | 2017-11-09 | Regents Of The University Of Michigan | Piperidines as menin inhibitors |
| JP7007302B2 (ja) | 2016-06-10 | 2022-01-24 | ヴァイティー ファーマシューティカルズ，エルエルシー | メニン－ｍｌｌ相互作用の阻害剤 |
| JP2019529421A (ja) | 2016-09-16 | 2019-10-17 | ヴァイティー ファーマシューティカルズ，エルエルシー | ｍｅｎｉｎ−ＭＬＬ相互作用の阻害剤 |
| WO2018106818A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
| AU2018243586A1 (en) | 2017-03-31 | 2019-10-17 | The Regents Of The University Of Michigan | Piperidines as covalent menin inhibitors |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| WO2019060365A1 (en) | 2017-09-20 | 2019-03-28 | Kura Oncology, Inc. | SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE |
| CN112105621B (zh) | 2018-03-30 | 2024-02-20 | 住友制药株式会社 | 光学活性桥型环状仲胺衍生物 |
| EP3856173A4 (en) | 2018-09-26 | 2022-07-06 | Kura Oncology, Inc. | TREATMENT OF HEMOPATHY MALIGNANCE WITH MENIN INHIBITORS |
-
2017
- 2017-05-02 WO PCT/US2017/030577 patent/WO2017192543A1/en not_active Ceased
- 2017-05-02 KR KR1020187034933A patent/KR20190015275A/ko not_active Ceased
- 2017-05-02 SG SG11201809714TA patent/SG11201809714TA/en unknown
- 2017-05-02 CA CA3022868A patent/CA3022868A1/en not_active Abandoned
- 2017-05-02 US US16/098,147 patent/US10899738B2/en not_active Expired - Fee Related
- 2017-05-02 ES ES17722968T patent/ES2899936T3/es active Active
- 2017-05-02 EP EP17722968.9A patent/EP3452461B1/en not_active Not-in-force
- 2017-05-02 AU AU2017259436A patent/AU2017259436B2/en not_active Ceased
- 2017-05-02 JP JP2018557418A patent/JP6991585B2/ja not_active Expired - Fee Related
- 2017-05-02 BR BR112018072570A patent/BR112018072570A2/pt not_active IP Right Cessation
- 2017-05-02 MX MX2018013433A patent/MX384087B/es unknown
- 2017-05-02 CN CN201780040586.6A patent/CN109415337B/zh not_active Expired - Fee Related
-
2018
- 2018-10-31 IL IL262697A patent/IL262697B/en active IP Right Grant
-
2020
- 2020-11-23 US US17/101,323 patent/US20210198237A1/en not_active Abandoned
-
2021
- 2021-03-02 IL IL281182A patent/IL281182A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN109415337B (zh) | 2022-01-18 |
| WO2017192543A1 (en) | 2017-11-09 |
| BR112018072570A2 (pt) | 2019-02-19 |
| CA3022868A1 (en) | 2017-11-09 |
| KR20190015275A (ko) | 2019-02-13 |
| JP6991585B2 (ja) | 2022-01-12 |
| US20210198237A1 (en) | 2021-07-01 |
| IL262697A (en) | 2018-12-31 |
| JP2019514950A (ja) | 2019-06-06 |
| US10899738B2 (en) | 2021-01-26 |
| SG11201809714TA (en) | 2018-11-29 |
| ES2899936T3 (es) | 2022-03-15 |
| IL262697B (en) | 2021-04-29 |
| IL281182A (en) | 2021-04-29 |
| MX2018013433A (es) | 2019-07-18 |
| AU2017259436B2 (en) | 2021-08-26 |
| AU2017259436A1 (en) | 2018-12-20 |
| CN109415337A (zh) | 2019-03-01 |
| EP3452461B1 (en) | 2021-09-08 |
| EP3452461A1 (en) | 2019-03-13 |
| US20190152947A1 (en) | 2019-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX384087B (es) | Piperidinas como inhibidores de menina. | |
| EA201992320A1 (ru) | Пиперидины в качестве ковалентных ингибиторов менина | |
| WO2018044767A3 (en) | Aminopyrimidines as alk inhibitors | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| MX381588B (es) | N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2. | |
| MX383935B (es) | Amidas heterocíclicas como inhibidores de cinasa. | |
| MY192521A (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
| PH12017501326A1 (en) | Tgf-� inhibitors | |
| MX384905B (es) | Degradadores de proteínas de bromodominio y dominioextraterminal (bet). | |
| MX2023006257A (es) | Inhibidores de smyd. | |
| MX2018000396A (es) | Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4). | |
| NZ727185A (en) | Phosphatidylinositol 3-kinase inhibitors | |
| MX381417B (es) | Inhibidores de glucosidasa. | |
| MX2017002986A (es) | Compuestos de piperidina sustituidos. | |
| MX2016016516A (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
| MX2021014531A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| EA201690127A1 (ru) | Состав на основе ингибиторов syk | |
| MX2020010181A (es) | Compuestos de piperidina como inhibidores covalentes de menina. | |
| PH12015502611A1 (en) | Heterocyclic compounds as hedgehog signaling pathway inhibitors | |
| MX2016016530A (es) | Inhibidores de fosfatidilinositol 3-quinasa. | |
| MX2016009352A (es) | Inhibidores de quinasa a base de quinolina. | |
| MX390051B (es) | Antagonistas de ep4. | |
| MX2016002764A (es) | Compuestos de triazolopiridina, composiciones y metodos de uso de los mismos. | |
| MX2016007810A (es) | Derivados de n1-(3,3,3-trifluoro-2-hidroxo-2-metilpropionil)-piper idina como inhibidores de piruvato deshidrogenasa cinasa. | |
| MX2015012600A (es) | Compuestos de tetrahidroisoquinolina-2-il-(quinazolina-4-il) metanona como inhibidores del crecimiento de células cancerígenas. |